- Home
- GENK vs RNXT Comparison
GENK vs RNXT Comparison
Compare GENK & RNXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GENK
- RNXT
- Stock Information
- Founded
- GENK 2011
- RNXT 2012
- Country
- GENK United States
- RNXT United States
- Employees
- GENK N/A
- RNXT N/A
- Industry
- GENK Restaurants
- RNXT Biotechnology: Pharmaceutical Preparations
- Sector
- GENK Consumer Discretionary
- RNXT Health Care
- Exchange
- GENK Nasdaq
- RNXT Nasdaq
- Market Cap
- GENK 27.9M
- RNXT 34.0M
- IPO Year
- GENK 2023
- RNXT 2021
- Fundamental
- Price
- GENK $5.65
- RNXT $1.02
- Analyst Decision
- GENK Strong Buy
- RNXT Strong Buy
- Analyst Count
- GENK 3
- RNXT 1
- Target Price
- GENK $12.17
- RNXT $9.00
- AVG Volume (30 Days)
- GENK 206.0K
- RNXT 134.5K
- Earning Date
- GENK 03-06-2025
- RNXT 05-09-2025
- Dividend Yield
- GENK N/A
- RNXT N/A
- EPS Growth
- GENK 62.05
- RNXT N/A
- EPS
- GENK 0.13
- RNXT N/A
- Revenue
- GENK $208,380,000.00
- RNXT N/A
- Revenue This Year
- GENK $20.99
- RNXT N/A
- Revenue Next Year
- GENK N/A
- RNXT N/A
- P/E Ratio
- GENK $44.87
- RNXT N/A
- Revenue Growth
- GENK 15.12
- RNXT N/A
- 52 Week Low
- GENK $5.00
- RNXT $0.77
- 52 Week High
- GENK $14.46
- RNXT $1.69
- Technical
- Relative Strength Index (RSI)
- GENK 47.16
- RNXT 46.22
- Support Level
- GENK $5.30
- RNXT $0.91
- Resistance Level
- GENK $7.41
- RNXT $1.03
- Average True Range (ATR)
- GENK 0.59
- RNXT 0.07
- MACD
- GENK 0.08
- RNXT 0.01
- Stochastic Oscillator
- GENK 26.97
- RNXT 77.78
About GENK GEN Restaurant Group Inc.
GEN Restaurant Group Inc is an Asian casual dining restaurant in the United States. It offers an extensive menu of traditional Korean and Korean-American food, including high-quality meats, poultry, seafood, and mixed vegetables.
About RNXT RenovoRx Inc.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.